Project Grant K23HL168161
Award Date
8/15/24
Completion Date
7/31/29
Dollars Obligated
$321K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Washington, DC 20010, USA
Similar Awards
This $163,080 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will support a multidimensional analysis of the regulatory T cell (Treg) response in children with severe viral pneumonia. The primary investigator will conduct research to determine if Treg cells have impaired reparative functions during severe viral pneumonia in juvenile mice, investigate how the age-specific lung microenvironment affects...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $561,030 to the Children's Research Institute to study the impact of CD52 knockout on the function of multi-virus-specific T cells. The goal is to determine if CD52 knockout can enable T cell persistence and efficacy in the presence of the immunosuppressive drug alemtuzumab. Key activities include optimizing CRISPR/Cas9 editing of virus-specific T cells,...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $180,199 to the Research Institute at Nationwide Children's Hospital in Columbus, Ohio. The objective is to identify myeloid-derived suppressor cells (MDSC) as contributors to the immune response in children with viral lower respiratory tract infections (LRTI) and to investigate the PD-1 pathway as a potential therapeutic...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $153,117 to support a 5-year research project focused on improving hematopoietic stem cell (HSPC) transplantation outcomes. The goal is to investigate mechanisms of HSPC-niche cell crosstalk, specifically how HSPC-derived extracellular vesicles promote remodeling of bone marrow endothelial cells and migration of HSPCs. The...
This Project Grant award of $194,740 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to characterize the development of lung-resident, self-antigen-specific regulatory T cells (Tregs) following acute lung injury. The goal is to understand how these "experienced" Tregs can promote tolerance and prevent future autoimmunity. The principal investigator, Dr. Daniel Shin at...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $131,211 to The Leland Stanford Junior University to conduct research on "High-Resolution Tracking of T Cell Differentiation to Predict and Control Alloreactive Disease" related to allogeneic hematopoietic stem cell transplantation. The overarching goal is to use high-resolution sequencing techniques to identify and track alloreactive T cells in order to...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $1,999,247 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Childrens Hospital Medical Center in Cincinnati, OH. The grant, entitled "Allogeneic Virus-Specific T-Cell Therapy After Hematopoietic Stem Cell Transplant: Determinants of Treatment Success and Failure", aims to improve understanding of the mechanisms underlying success and failure of virus-specific T-cell (VST) therapy in...
This Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $248,955 to Howard University from March 1, 2025 to February 29, 2028. The grant supports research to characterize the roles of bivalent chromatin domains in regulating cellular plasticity during CD4+ T cell differentiation. Key objectives include: 1) identifying plasticity-related bivalent domains that dynamically change during T cell...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $169,156 to The Washington University in St. Louis to support a 5-year research program focused on optimizing hematopoietic stem cell transplantation (HSCT) to treat non-malignant diseases, particularly sickle cell disease (SCD). The key objectives are to: 1) Evaluate novel stem cell mobilization regimens combining VLA-4 and CXCR4 inhibition to generate...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $1,123,357.00 to support research on the bone marrow microenvironment and its role in regulating blood cell production. The research, to be conducted by the Children's Hospital Medical Center in Cincinnati, Ohio, aims to define the spatial organization and specialized vascular microenvironments within the bone marrow that recruit and...